Gsk Plc · LSE:GSK
Gsk — Investor Presentation (2011)
30 slides from Gsk's investor presentation, 2011
Slide 1: GSK Vaccines in 2011
GSK VACCINES IN 2011 Martin Andrews Senior Vice President Global Vaccines Centre of Excellence GSK Biologicals
Slide 2: Today's agenda
Today’s agenda GSK GSK Global GSK vaccines: vaccines vaccines vaccines key growth pipeline market in 2011 drivers 2
Slide 3: Vaccines business characteristics
Vaccines business characteristics Few global players and high barriers to entry – Complex manufacturing – Large scale investment Long product life cycles – Complex intellectual property High probability of R&D success – 70% post-POC New technology/novel products Better pricing for newer vaccines – H
Slide 4: Global vaccines market 2010
Global vaccines market 2010 2010 total sales 2010 excluding H1N1 Novartis Novartis 12.7% 8.3% GSK Bio GSK Bio 25.0% 29.1% Pfizer Pfizer 18.8% 15.9% 2009 2009 2009 Merck Merck Sanofi- Sanofi- 18.0% Aventis 15.2% Aventis 23.6% SP-MSD SP-MSD 21.9 % 5.3% 6.3% Total 2010 = $23,066m Total 2010 excl. H1N1
Slide 5: Millions of children die from infectious diseases
Millions of children die from infectious diseases Many of these deaths are preventable By 2015 vaccines could reduce these deaths by 90% YF, Diphtheria, Tetanus Polio, Hep B 5% 0% Malaria Pertussis 29% 7% Measles 13% HIV 9% Hib 9% TB 1% Launched Meningitis A/C Rotavirus Japanese In development 10% e
Slide 6: Today's agenda
Today’s agenda GSK GSK Global GSK vaccines: vaccines: vaccines vaccines key growth therapeutic market in 2010 drivers vaccines 6
Slide 7: GSK vaccines business in 2010
GSK vaccines business in 2010 2010 sales £4.3 billion (+15%) Vaccines represent 15% of total GSK sales +18% CAGR excl. H1N1 since 2005 Over 30 approved vaccines and Sale s 20 in development (£m) 5000 4500 4000 Distributed 1.43 billion vaccine doses 3500 to 179 countries in 2010 3000 2500 Approximate
Slide 8: GSK vaccines: a history of growth
GSK vaccines: a history of growth GSK vaccines 2010 sales £4.3bn (+15%) £m 5000 4500 81 4000 86 687 3500 203 669 927 3000 65 2500 158 1004 85 462 950 2000 123 81 108 318 1500 78 700 294 106 259 667 1000 516 1744 364 1681 1155 500 694 799 581 0 2005 2006 2007 2008 2009 2010 Europe North America Emerg
Slide 9: GSK Emerging Markets business
GSK “Emerging Markets” business 85 countries CIS China MENA India Mexico SSA Latin America Emerging Markets FY2010 Vaccines Sales £927mn (+38%)* = 21% of Total GSK Vaccines Sales 9 *Note: GSK FY2010 sales including pandemic
Slide 10: GSK's pharma presence in Emerging Markets
GSK’s pharma presence in Emerging Markets Eastern & CIS Central Europe China MENA India Mexico SSA Asia Pac Latin (excl Japan, Aus, NZ) America 10
Slide 11: Emerging Markets strategy
Emerging Markets strategy FY2010 Turnover Scale up our Classic brands Build and capture the business Vaccines market £1.6bn +18% £927m +38% £701m +14% excl. pandemic Pandemic Drive our Innovative brands £1.0bn +16% ; Source: GSK FY2010 reported sales; CER growth rates 11
Slide 12: Vaccines represent 5 of Top 10 GSK EM brands
Vaccines represent 5 of Top 10 GSK EM brands 12
Slide 13: Build and capture the EM vaccines market
Build and capture the EM vaccines market Significant market GSK has 38% of the growth potential market and is growing faster Growing government attention to public health agenda £927M(+38%) Large birth cohorts for GSK EM Vaccines 2010 paediatric vaccines Significant GSK growth potential Established
Slide 14: GSK has the broadest vaccine portfolio across EM
GSK has the broadest vaccine portfolio across EM GSK Merck Sanofi Pfizer Novartis DTPw combos 9 9 9 DTPa combos 9 9 MMR / Varicella 9 9 9 Hepatitis A 9 9 9 Rotavirus 9 9 Meningococcal 9 9 9 Pneumococcal 9 9 Influenza 9 9 9 HPV 9 9 Malaria d Dengue d d 9 = available in EM; d = in development 14
Slide 15: Emerging markets opportunity: China & Brazil
Emerging markets opportunity: China & Brazil China Licensed vaccines • Infanrix, Infanrix-Hib, Boostrix, Fluarix, Engerix-B, Hiberix, Havrix, Twinrix, Priorix, Varilrix Vaccines in development £122m • Cervarix (phase III trials ongoing in China); Infanrix-IPV/Hib (IND) +3% Joint venture with Neptunu
Slide 16: Today's agenda
Today’s agenda GSK GSK Global GSK vaccines: vaccines vaccines vaccines key growth pipeline market in 2010 drivers 16
Slide 17: GSK key vaccines: 2010 sales
GSK key vaccines: 2010 sales Synflorix Boostrix £221m £181m Cervarix £242m Fluarix/FluLaval £241m Pandemic Flu £1,192m Rotarix £235m Other Vaccines Hepatitis £594m £720m Infanrix/Pediarix £700m 2010 sales: £4.3 billion (+15%) 17
Slide 18: GSK Vaccines: base business
GSK Vaccines: base business Strong heritage in paediatric and hepatitis vaccines including several world firsts Significant sales contribution from – Infanrix family £700m; +8% (2010) – Hepatitis £720m; +7% (2010) – Boostrix £181m; +29% (2010) Continuing innovation – Heptavalent combination vaccine
Slide 19: Influenza: seasonal & pandemic
Influenza: seasonal & pandemic Seasonal influenza sales of £241 million in 2010 – £40 million in Emerging Markets Largest global supplier of H1N1 pandemic vaccine – Doses supplied to over 60 countries – Approximately £2.0 billion sales £883 million (2009) £1,192 million (2010) – 60 million dose dona
Slide 20: Synflorix: successful launch
Synflorix: successful launch Approved in 95 countries Filed in additional 19 countries Significant tender wins and market share gains 2010 sales £221 million Strongest GSK launch in EM in a decade 2010 EM sales £149 million S. pneumoniae causes 700,000 - 1 million deaths annually Ten countries accou
Slide 21: Rotarix in 2010: returning to growth
Rotarix in 2010: returning to growth Approved in 121 countries Filed in Japan (November 2009) 2010 sales £235 million 2010 EM sales £102 million Key national tender wins Significant private market share in EM Disease burden in EM is significant 600,000 children die from RVGE & 2 million are hospital
Slide 22: Cervarix in 2010: future opportunities
Cervarix in 2010: future opportunities Approved in 112 countries Including US and Japan 2010 sales £242 million (+26%) Japan 2010 sales £57 million (>100%) Improved EU & International label Includes cross-protection Over half of competitive tenders won Over two-thirds by volume WHO Prequalification
Slide 23: Today's agenda
Today’s agenda GSK GSK Global GSK vaccines: vaccines vaccines vaccines key growth pipeline market in 2010 drivers 23
Slide 24: GSK vaccines: a rich pipeline
GSK vaccines: a rich pipeline Phase I Phase II Phase III Submitted HIV Tuberculosis Mosquirix™ MenHibrix™ Prophylaxis Malaria (HibMenCY-TT) HibMenCY-TT Pandemic influenza New generation Seasonal influenza Nimenrix™ MMR H5N1 cell-culture seasonal flu Qaudrivalent (MenACWY-TT) MenACWY-TT PRAME ASCI WT
Slide 25: Late-stage assets: meningitis
Late-stage assets: meningitis Meningococcal disease causes permanent disability or death – Fatality rate 9-12%1 Five serogroups (A, B, C, W135, Y) cause the majority of invasive meningococcal disease GSK developing tailored meningitis vaccines to fulfil regional and age- related needs: – Nimenrix (M
Slide 26: Late-stage assets: Mosquirix (RTS,S)
Late-stage assets: Mosquirix (RTS,S) Significant burden of disease – Malaria kills almost 900,000 people every year1 Many in sub-Saharan Africa Majority are children under the age of five Phase III trials underway – 11 trial sites across 7 African countries – Enrolment complete (15,461) 8,923 childr
Slide 27: Late-stage assets: Herpes zoster
Late-stage assets: Herpes zoster • Herpes zoster (HZ) & Post-herpetic neuralgia (PHN) • After initial varicella zoster infection (chickenpox), VZV DNA remains latent Rate per in nerve cells 1.000 / year 12 • May reactivate later in life to cause HZ 1 (shingles) Zoster 1 PHN 10 • 1 in 4 will suffer f
Slide 28: Therapeutic vaccines
Therapeutic vaccines ASCI Nicotine Addiction Alzheimer’s Four ASCIs in development Nicotine conjugate vaccine Candidate vaccines • MAGE-A3, WT1, PRAME & (NicVAX)1 in development2 NY-ESO-1 Targets beta-amyloid Aid to smoking cessation and Three tumour types long-term abstinence • Pivotal role in plaq
Slide 29: GSK vaccines in 2011
GSK vaccines in 2011 A world leader in vaccines One of the broadest portfolios and fastest growing vaccines businesses in the world Strong pipeline including innovative therapeutic vaccine approaches Flexibility of GSK vaccines business model – Partnerships (JVs, technology transfer) – Pricing (Tier
Slide 30: GlaxoSmithKline
GlaxoSmithKline